Last reviewed · How we verify
Cyclophosphamide, Fludarabine, Thymoglobulin
This combination regimen uses chemotherapy and immunosuppression to eliminate malignant and autoreactive cells before hematopoietic stem cell transplantation.
This combination regimen uses chemotherapy and immunosuppression to eliminate malignant and autoreactive cells before hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in pediatric hematologic malignancies, Preparation for allogeneic bone marrow transplantation.
At a glance
| Generic name | Cyclophosphamide, Fludarabine, Thymoglobulin |
|---|---|
| Sponsor | The Korean Society of Pediatric Hematology Oncology |
| Drug class | Chemotherapy regimen with immunosuppressive agent |
| Modality | Small molecule |
| Therapeutic area | Oncology / Hematology |
| Phase | Phase 2 |
Mechanism of action
Cyclophosphamide is an alkylating agent that cross-links DNA and causes cell death; Fludarabine is a purine analog that inhibits DNA synthesis; Thymoglobulin (anti-thymocyte globulin) is a polyclonal antibody that depletes T cells. Together, they provide myeloablative conditioning and immunosuppression to prepare the bone marrow for transplantation and reduce graft rejection and graft-versus-host disease.
Approved indications
- Conditioning regimen for hematopoietic stem cell transplantation in pediatric hematologic malignancies
- Preparation for allogeneic bone marrow transplantation
Common side effects
- Myelosuppression / neutropenia
- Infection
- Mucositis
- Hemorrhagic cystitis
- Graft-versus-host disease
- Nausea and vomiting
Key clinical trials
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) (PHASE2)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Stem Cell Transplantation in Crohn's Disease (PHASE1, PHASE2)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab (PHASE1, PHASE2)
- Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: